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Abstract
This study examined whether sleep disturbance predicted or moderated responses to 
psychotherapy in participants who participated in STEP-BD, a national, multi-site study that 
examined the effectiveness of different treatment combinations for bipolar disorder. Participants 
received either a brief psychosocial intervention called collaborative care (CC; n=130), or 
intensive psychotherapy (IP; n=163), with study-based pharmacotherapy. Participants (N=243) 
were defined as current (past week) short sleepers (<6 hours/night), normal sleepers (6.5-8.5 
hours/night), and long sleepers (≥9 hours/night), according to reported average nightly sleep 
duration the week before randomization. Sleep disturbances did not predict the likelihood of 
recovery nor time until recovery from a depressive episode. There was no difference in recovery 
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rates between IP versus CC for normal sleepers, and medium effect sizes were observed for 
differences in short and long sleepers. In this study, sleep did not play a major role in predicting or 
moderating response to psychotherapy in bipolar disorder.
Keywords
sleep disturbance; insomnia; hypersomnia
Introduction
Bipolar disorder is a severe psychiatric illness characterized by episodes of mood elevation 
and depression. Individuals with this disorder have significant functional impairment, 
reduced quality of life, and a high risk of suicidality (Kilbourne et al., 2004; Novick, Swartz, 
& Frank, 2010). Pharmacotherapy is considered the foundation of treatment for this chronic 
disorder (Geddes & Miklowitz, 2013); however, use of medications alone often fails to bring 
patients to full and sustained remission (Frank, Swartz, & Kupfer, 2000). The limited 
efficacy of pharmacotherapy alone highlights the need for adjunctive psychosocial 
interventions (Lauder, Berk, Castle, Dodd, & Berk, 2010).
When psychotherapy is paired with pharmacotherapy, participants experience reduced rates 
of relapse, improved medication adherence, reduced residual mood symptoms, and improved 
overall psychosocial functioning (Miklowitz, George, Richards, Simoneau, & Suddath, 
2003; Miklowitz, 2008; Otto & Miklowitz, 2004). However, there is considerable variability 
in response rates in clinical trials of psychotherapy, pointing to the need to identify 
moderators of treatment response.
Sleep disturbance is a common prodromal feature of bipolar disorder and a precipitant of 
mood episodes (Jackson, Cavanagh, & Scott, 2003). Sleep disturbance often precedes the 
onset of both manic and depression symptoms, and it worsens after episode onset (Bauer et 
al., 2006; Colombo, Benedetti, Barbini, Campori, & Smeraldi, 1999; Harvey, Schmidt, 
Scarnà, Semler, & Goodwin, 2005; Jackson et al., 2003). Moreover, during mood episodes, 
short sleep duration, which is indicative of insomnia, is associated with more severe 
symptoms, and both short and long sleep duration are associated with poorer functioning 
and quality of life. Sleep disturbance is also present during periods of relative remission 
(Harvey et al., 2005). Psychotherapy (e.g. cognitive behavioral therapy, interpersonal 
psychotherapy) is associated with decreased rapid eye movement (REM) density in 
individuals with unipolar depression (Buysse, Frank, Lowe, Cherry, & Kupfer, 1997; 
Nofzinger et al., 1994). During remission, instability in sleep and biological rhythms are 
correlated with levels of the disability in bipolar disorder (Giglio, Magalhaes, Kapczinski, 
Walz, & Kapczinski, 2010).
To better understand the role of sleep in treatment outcomes for bipolar disorder, the current 
study investigated whether sleep disturbance (defined as shorter or longer sleepers) mediates 
or moderates the likelihood that patients recover from depression in response to intensive 
psychotherapy or collaborative care in the Systematic Treatment Enhancement Program for 
Bipolar Disorder (STEP-BD). STEP-BD, a National Institute of Mental Health-sponsored 
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study of the effectiveness of treatments for bipolar disorder, found that adjunctive, intensive 
psychotherapy, as compared to brief psychoeducation (collaborative care), was more 
beneficial in achieving and reducing time to recovery from a depressive episode (Miklowitz 
et al., 2007). We hypothesized that 1) STEP-BD participants who are normal sleepers will 
have higher recovery rates from mood episodes and will recover in less time compared to 
short or long sleepers; and 2) individuals with sleep disturbance (i.e., short or long sleepers) 
would be more likely to achieve recovery with intensive psychotherapy than with 
collaborative care.
Method
Study Design
STEP-BD was a national, multi-site study that examined the effectiveness of different 
treatment combinations for symptoms of bipolar disorder, including various 
pharmacotherapy and psychosocial interventions. STEP-BD was the largest longitudinal 
treatment outcome study in bipolar disorder, enrolling 4,361 subjects across 21 sites (Sachs 
et al., 2003). Ethical approval was obtained by each site's respective human research 
committee (Sachs et al, 2003). Individuals in STEP-BD, who were currently in a depressive 
episode, were offered to participate a randomized control trial comparing adjunctive 
intensive psychotherapy to a control group in 15 clinics (Miklowitz et al., 2007). In this trial, 
participants, after giving additional written informed consent, were randomly assigned to 
either 6 weeks of treatment (up to 3 sessions) with collaborative care (CC; N=130) or 9 
months of weekly treatment (up to 30 sessions) with intensive psychotherapy (cognitive 
behavioral therapy [CBT; N=75], family focused therapy [FFT; N=26], or interpersonal 
social rhythm therapy [IPSRT; N=62]) (Miklowitz et al., 2007).
Collaborative care was a brief intervention that focused on psychoeducation about bipolar 
disorder and employed some of the most common psychosocial strategies shown to be 
beneficial for bipolar disorder (Miklowitz et al., 2007). CBT emphasized challenging 
negative thoughts and dysfunctional beliefs, cognitive restructuring, and problem solving 
training (Lam, Hayward, Watkins, Wright, & Sham, 2005). FFT focused on educating the 
participants' family members about bipolar disorder and the family unit's impact on the 
illness course. It also emphasized improving communication and problem solving in the 
home environment (Miklowitz et al., 2000). IPSRT stressed the importance of social rhythm 
stability for prevention of mood disruptions by developing plans for mood and social rhythm 
stability, and learning strategies to manage interpersonal conflicts such as grief, relationship 
difficulties, or role disputes (Frank et al., 2000; Frank et al., 2005).
Participants
Participants (n = 293) were eligible for the study if they met DSM-IV criteria for bipolar I or 
II disorders and a current major depressive episode, and were currently being treated or 
willing to be treated with a mood stabilizer. If participants were currently undergoing 
psychotherapy, they could enroll in the study if they discontinued non-study related 
psychotherapy or reduce the sessions to one or fewer per month. Participants were excluded 
if they needed treatment for substance/alcohol abuse or dependence, were pregnant, had a 
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history of nonresponse or intolerance to the antidepressant study drugs, or required initial 
use or changes to their antipsychotic medications (For a more detailed summary of 
inclusion/exclusion criteria, see Miklowitz et al., 2007). Depending on what arm of the main 
study they were in, participants were randomly assigned to double-blind pharmacotherapy 
with mood stabilizers (lithium, valproate, or carbamazepine), placebo plus adjunctive 
antidepressants (buproprion or fluoxetine), or a combination of mood stabilizer and 
antipsychotic medications according to patient-physician agreement and guidelines outlined 
in STEP-BD for best practice evidence-based pharmacotherapy (Sachs et al., 2003) Included 
in these analyses is a subset (n = 243; 83%) of randomized participants (n = 293), who 
provided information both at study entry and throughout study participation regarding their 
minimum and maximum sleep duration from the past week on the Clinical Monitoring Form 
(CMF; Sachs et al., 2003). Trained clinicians, specializing in the assessment of bipolar 
symptoms, would use weekly milestones, such as work, seeing friends and family, or the day 
of the week to help them remember the most and least amount of sleep that they had over the 
past week.
Sleep Functioning Measures
Sleep duration was operationally defined as the average number of hours of sleep in the past 
week. This average was calculated using the minimum and maximum sleep duration values 
from the prior week reported on the CMF (Gruber et al., 2009). Participants were divided 
into three groups based on their average nightly sleep duration the week prior to baseline: 
short sleepers, normal sleepers, and long sleepers. Short sleepers were defined as those with 
an average of < 6 hours of sleep per night, normal sleepers as those with an average 6.5 - 8.5 
hours per night, and long sleepers as those with ≥ 9 hours of sleep per night. These cutoffs 
have been validated in other studies based on their distinct clinical correlates (Edinger et al., 
2000; Gruber et al., 2009; Kaneita et al., 2007).
Assessment of Treatment Outcomes
Diagnoses and Psychiatric History—Diagnoses of bipolar disorder relied on the 
consensus of two trained clinicians: a clinical specialist (a psychologist or social worker) 
who administered the Mini International Neuropsychiatric Interview (MINI; Sheehan et al., 
1998) and a psychiatrist who administered a standardized affective disorder evaluation 
(ADE; Sachs, 1990). Diagnosis of anxiety disorders relied on the MINI, and psychiatric 
history (e.g., number of previous bipolar episodes) were captured on the ADE.
Mood Symptoms—During each treatment visit, participants' mood symptoms were 
assessed using the CMF. Participants reporting ≤ 2 moderate mood symptoms (depression 
and mania/hypomania) for ≥ 8 consecutive weeks were given a clinical status designation of 
“recovered.” Participants were considered “not recovered” if they reported ≥ 3 depressive or 
manic/hypomanic symptoms (Sachs et al., 2003). Interrater reliability coefficients 
(according to gold standard ratings for depression and mania ratings in the CMF) ranged 
from 0.83 to 0.99 (intraclass correlations).
Overall Functioning—The Global Assessment of Functioning (GAF) scale is scored on a 
numeric scale (range: 0=inadequate information to 100=superior functioning) and is widely 
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used to rate the social, occupational, and psychological functioning of adults (Hall, 1995). 
The modified Global Assessment of Functioning (GAF) scale has more detailed criteria and 
a more structured scoring system than the original GAF. Scores were based on the judgment 
of trained study research staff after completing their clinical interview.
Data Analyses
To evaluate whether sleep group (short, normal, or long sleepers) predicted recovery rates 
and time until recovery, we conducted logistic regression and Cox proportional hazard 
(survival) models. Participants were included until their final assessment point, which was a 
maximum of 365 days (M=166.48, SD=102.58; Sachs et al., 2003). To evaluate the ability of 
sleep group to predict recovery status after adjusting for treatment effects, treatment 
condition (intensive psychotherapy or collaborative care) was included in the model as an 
independent variable, and participants who were normal sleepers were compared to short 
and long sleepers in terms of recovery status. Demographic, mood, and medication variables 
that differed across sleep groups were entered as predictors into the regression models.
To examine whether sleep disturbance moderated treatment outcome, we added an 
interaction term with treatment condition to our models predicting recovery rates and time 
until recovery. We followed Kraemer and Kupfer's (2006) recommendations for examining 
exploratory moderators of treatment outcome in randomized controlled trials, using effect 
sizes. We examined the magnitude of the treatment effects at each proposed moderator level 
(Kraemer & Kupfer, 2006) and 95% confidence intervals, as indicated by the Newcombe-
Wilson score method without continuity correction (Newcombe, 1998).
To illustrate the magnitude of effect sizes, we used the Number Needed to Treat (NNT) 
effect size, which is most robust for examining the clinical significance of binary outcomes 
(Altman & Andersen, 1999; Cook & Sackett, 1995; Cook & Sackett, 1995). NNT is the 
number of patients one would expect to treat with the investigational treatment, or intensive 
psychotherapy, in order to have one more patient respond to the treatment than if the same 
number was treated with the control treatment (Deckersbach et al., 2014). An NNT value of 
2 is considered large, 3.5 is medium, and effect sizes greater than 9 are small (Kraemer & 
Kupfer, 2006). We compared short sleepers, normal sleepers, and long sleepers on the 
magnitude of the between group (collaborative care vs. psychotherapy) effect size. NNT for 
“recovered” status was examined separately for participants in each sleep group and 
treatment condition according to the average number of hours they reported sleeping per 
night at their baseline visit.
Additionally, for each sleep group, a 3 × 2 × 2 mixed model analysis of variance 
(MANOVA) was used to examine the change in sleep duration within subjects and across 
sleep groups and treatment arms, with sleep group (short sleepers, normal sleepers, and long 
sleepers) and treatment group (intensive psychotherapy, collaborative care) as the between 
subjects factors and study visit (pre-, post- intervention) as the within subjects factor.
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Results
Study Sample
Table 1 shows the demographic and clinical characteristics of the 243 depressed bipolar 
participants. The average age was 40.32 (SD = 11.47), 60% (n = 146) were female, and 61% 
(n=136) had bipolar I disorder. There were no significant differences in demographic and 
clinical characteristics between our sample and the 50 participants with no CMF sleep data 
(data not shown).
Psychosocial Treatment Outcome
Participants demonstrated significantly higher year end recovery rates if they were randomly 
assigned to intensive psychotherapy than collaborative care, χ2(1, n = 243) = 4.00, p < .05. 
These findings are consistent with the results found in the full sample (n = 293; Miklowitz et 
al., 2007).
Clinical and Demographic Variables by Sleep Group
Out of the 243 participants with baseline sleep data available, 67 were identified as short 
sleepers, 99 as long sleepers, and 77 as normal sleepers. The subgroups did not differ in sex, 
education, marital status, bipolar subtype, depressive symptom severity, or having a lifetime 
anxiety disorder (all p's > .18; see Table 1). There were differences among the three groups 
in baseline manic symptom severity, F(2, 242) = 2.95, p = .05, and mood stabilizer usage, 
χ2(2, n = 238) = 7.61, p < .05. There were statistical trends towards differences in global 
functioning (GAF) scores, F(2, 235) = 2.69, p = .07, atypical antipsychotic usage, χ2(2, n = 
238) = 4.00, p = .07, and anticonvulsant usage, χ2(2, n = 238) = 5.43, p = .06 (Table 1).
Pairwise comparisons showed that short sleepers had greater mania severity than long 
sleepers, t(240, n = 236) = 2.35, p < .05. Compared to normal sleepers, short sleepers were 
significantly more likely to be taking mood stabilizers χ2 (1, n = 141) = 6.96, p < .05, but 
less likely to be taking atypical antipsychotics χ2(1, n = 141) = 4.58, p < .05. Normal 
sleepers were significantly less likely than long sleepers to be taking mood stabilizers χ2 (1, 
n = 171) = 5.15, p < .05, and anticonvulsants χ2 (1, n = 171) = 4.96, p < .05. Short sleepers 
were also significantly less likely to take atypical antipsychotics than long sleepers χ2 (1, n 
= 164) = 4.04, p < .05. Note the varying degrees of freedom are due to missing values. 
Binary logistical regressions showed that baseline mania severity did not significantly 
predict recovery rates in any of the sleep groups (all p's > .12).
Does Sleep Type Predict Recovery or Time to Recovery?
Logistic and Cox regressions were used to examine predictors of recovery and time to 
recovery. Treatment group, sleep group, baseline GAF, and medication use (anticonvulsants, 
atypical antipsychotics, other mood stabilizers) were entered as additional predictors in the 
models. Results of the modeling sequence are shown in Table 2. Sleep group (short, long, 
normal) did not predict likelihood of recovery (p's > .41; see Table 2) nor time until recovery 
(p's > .57). Higher baseline GAF scores and increased mood stabilizer use (not Lithium) 
significantly predicted recovery (p's < .05) but not time until recovery (p's > .16; see Table 
2).
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Moderator Analyses
The treatment interaction terms for sleep group did not reach significance for either model, 
so sleep group did not moderate recovery or time to recovery (p's > .20). Sixty-three percent 
(n = 25) of short sleepers recovered with intensive psychotherapy, whereas only 41% (n = 
11) recovered with collaborative care. This treatment response rate difference resulted in a 
medium effect size (NNT = 4.55; see Table 3). Thus, we would need to treat 4.55 short 
sleepers with IP rather than collaborative care to have an additional short sleeper recovering 
with IP. A similar pattern of effects was observed for long sleepers. Seventy percent (n = 35) 
of long sleepers recovered with psychotherapy, whereas only 51% (n = 25) recovered with 
collaborative care. This treatment difference resulted in a medium effect size (NNT = 5.26; 
see Table 2). That is, we would need to treat 5.26 long sleepers with IP compared to 
collaborative care to have an additional long sleeper recover from IP. Finally, 57% of normal 
sleepers (n = 26) recovered with psychotherapy, and 58% (n = 18) recovered with 
collaborative care. These recovery rates corresponded to a very small effect size (NNT = 
100; see Table 3).
Changes in Sleep with Treatment
Table 4 shows the changes in average sleep duration post-treatment for each sleep group. 
The 3 × 2 × 2 MANOVA assessing sleep change as function of baseline sleep group and 
treatment indicated a significant main effect of sleep group, F(2, 237) = 192.7, p < .001, and 
study visit, F(1, 237) = 8.10, p < .01. There was no main effect of treatment group, F(1, 237) 
= 0.69, p = .41, indicating that sleep duration did not differ for intensive psychotherapy and 
collaborative care. There was a significant study visit by sleep group interaction, F(2, 237) = 
87.92, p < .001, indicating that change in sleep duration varied according to sleep group over 
the treatment phase. Sleep duration pre- to post-intervention increased for short sleepers 
(MPre- = 4.94, MPost- = 6.72), decreased for long sleepers (MPre- = 10.84, MPost- = 8.24), and 
did not change for normal sleepers. There was no study visit by treatment group interaction, 
indicating that change in sleep duration over treatment did not vary according to treatment 
condition. There was also no study visit by treatment group by sleep group interaction, or 
sleep group by treatment group interaction.
Discussion
The present study investigated whether sleep disturbance serves as a predictor and/or a 
moderator of psychotherapy response in depressed individuals with bipolar disorder. Sleep 
neither predicted the likelihood of recovery nor the time to recovery in our analyses. 
Contrary to our hypothesis, receiving intensive psychotherapy as opposed to collaborative 
care did not offer a major advantage in terms of recovery rates. This is somewhat surprising, 
as individuals with bipolar disorder who are poor sleepers may experience more stressors in 
their lives or have less ability to manage the stressors, which would be addressed in intensive 
psychotherapy, but not collaborative care. This hypothesis is consistent with prior studies 
indicating that stressful life events can have a negative impact on sleep quality (Bernert, 
Merrill, Braithwaite, Van Orden, & Joiner, 2007; Frank et al., 2000; Haynes, McQuaid, 
Ancoli-Israel, & Martin, 2006). Noteworthy shortcomings of the present study included that 
sleep duration was assessed by self-report which is vulnerable to recall bias, and we the 
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study did not include objective measures of sleep quantity or quality such as 
polysomnography or actigraphy (Fernandez-Mendoza et al., 2011; Mercer, Bootzin, & Lack, 
2002). Therefore, it is not possible to formally diagnose individuals with insomnia or 
hypersomnia. Future research should utilize objective measures or daily sleep diaries to 
provide more data on weekly sleep patterns. Randomization to treatment group was not 
stratified according to sleep-type, possibly confounding our finding of sleep on recovery. Of 
note, this study also does not examine the role of sleep on mania or hypomania on treatment 
response as participants were only enrolled if depressed at baseline. Further, due to sample 
size restrictions, we did not investigate the differential effects of the type of psychotherapy, 
which consisted of three treatments. Therefore, it is possible that the extent to which sleep 
was emphasized differed depending on the treatment modality received. Future research 
should more closely examine whether sleep patterns influence response to psychotherapy 
differentially depending on type of services. Lastly, the measure of sleep only covered the 
prior past week, and it would be useful to know if habitual long-term sleep patterns had a 
similar relationship. Furthermore, it is possible that sleep variability, rather than sleep 
duration alone may have a greater impact on treatment response. With these caveats in mind, 
in summary, our findings indicate that sleep during the past week does not seem to play a 
major role in predicting or moderating response to psychotherapy in bipolar disorder, 
suggesting that examining current sleep may not be a necessary factor that clinicians need to 
consider when determining the most appropriate type of psychosocial intervention for their 
patients.
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Table 1
Demographic and Illness Characteristics of 243 Depressed Bipolar Patients By Sleep 
Group
Short Sleepers (SS) Normal Sleepers (NS) Long Sleepers (LS) Overall
M ± SD M ± SD M ± SD M ± SD
Age 41.06 ± 9.98 40.43 ± 12.98 39.71 ± 11.27 40.32 ± 11.47
Depressive Severity 6.68 ± 2.20 6.31 ± 2.36 6.28 ± 1.85 6.40 ± 2.12
Mania Severitya 1.35 ± 1.04 1.21 ± 1.14 0.96 ± 0.96 1.15 ± 1.05
Number of Therapy Sessions 8.61± 9.79 9.23 ± 11.06 8.47± 9.91 8.75 ± 10.22
Baseline GAF 57.84 ± 8.70 54.93 ± 9.51 57.95 ± 9.20 56.96 ± 9.23
N (%) N (%) N (%) N (%)
Female Sex 44 (67) 42 (55) 60 (61) 146 (60)
Education >1 year college 52 (80) 57 (78) 75 (82) 184 (80)
Married 23 (34) 24 (32) 29 (30) 76 (32)
Diagnosis
 Bipolar I 33 (52) 42 (58) 61 (67) 136 (61)
 Bipolar II 30 (48) 30 (42) 30 (33) 90 (40)
Lifetime Anxiety Disorder 40 (63) 45 (63) 62 (68) 147 (65)
Age at illness onset
 < 15 17 (29) 17 (25) 25 (30) 59 (28)
 > 15 42 (71) 52 (75) 58 (70) 152 (72)
Number Lifetime Manic Episodes
 1-9 17 (30) 25 (38) 30 (37) 72 (36)
 10-20 15 (27) 6 (9) 11 (14) 32 (16)
 20+ 24 (43) 34 (52) 40 (49) 98 (49)
Number Lifetime Depressive Episodes
 1-9 23 (41) 23 (35) 21 (26) 67 (33)
 10-20 6 (11) 8 (12) 12 (15) 26 (13)
 20+ 27 (48) 34 (52) 48 (59) 109 (54)
# Anxiety Disorders
 0 23 (36) 28 (38) 29 (32) 80 (35)
 1 20 (32) 18 (25) 26 (29) 64 (29)
 2 11 (17) 16 (22) 16 (18) 43 (19)
 3 6 (10) 7 (10) 10 (11) 23 (10)
 4 1 (2) 3 (4) 9 (10) 13 (6)
 5 2 (3) 1 (1) 1 (1) 4 (2)
# Comorbid Conditions
 0 14 (21) 18 (23) 21 (21) 53 (22)
 1 19 (28) 11 (14) 18 (18) 48 (20)
 2 14 (21) 23 (30) 19 (19) 56 (23)
 3 20 (30) 25 (33) 41 (41) 86 (35)
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Short Sleepers (SS) Normal Sleepers (NS) Long Sleepers (LS) Overall
M ± SD M ± SD M ± SD M ± SD
Baseline Medications
 Antidepressants 31 (46) 30 (41) 40 (41) 101 (42)
 Atypical Antipsychoticsa,b 12 (18) 25 (34) 31 (32) 68 (29)
 Anxiolytics 19 (28) 19 (26) 27 (28) 65 (27)
 Anticonvulsantsc 37 (55) 30 (41) 56 (58) 123 (52)
 Lithium 21 (31) 27 (37) 30 (40) 78 (33)
 Other Mood Stabilizersb,c 25 (37) 13 (18) 32 (33) 70 (30)
Abbreviations: GAF (Global Assessment of Functioning), Depressive Severity (refers to summary score of depression symptoms [excluding sleep 
variables] from the Clinical Monitoring Form recorded within 1 week of the date of randomization to treatment), Mania Severity (refers to 
summary score of mania symptoms [excluding sleep variables] from the Clinical Monitoring Form recorded within 1 week of the date of 
randomization to treatment)
Notes: Where data points were missing, percentages are calculated out of total number of available cases. Diagnoses were determined using the 
Affective Disorders Evaluation.
a
Difference between short sleepers and long sleepers (p < .05)
b
Difference between short sleepers and normal sleepers (p < .05)
c
Difference between normal sleepers and long sleepers (p < .05)
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